Last €8.90 EUR
Change Today +0.02 / 0.23%
Volume 9.3K
MKEA On Other Exchanges
EN Paris
As of 11:35 AM 07/11/14 All times are local (Market data is delayed by at least 15 minutes).

mauna kea technologies (MKEA) Snapshot

Previous Close
Day High
Day Low
52 Week High
03/6/14 - €15.37
52 Week Low
07/10/14 - €8.75
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

Related News

No related news articles were found.

mauna kea technologies (MKEA) Related Businessweek News

No Related Businessweek News Found

mauna kea technologies (MKEA) Details

Mauna Kea Technologies S.A. engages in the design, development, and manufacture of medical devices for medical imaging. The company offers Cellvizio, a probe-based Confocal Laser Endomicroscopy solution that performs microscopic imaging. Its Cellvizio platform provides various Confocal Miniprobes to answer the specific needs of each endoscopy field comprising GastroFlex for Eso-Gastro-Duodenoscopy; CholangioFlex for Confocal Cholangioscopy in ERCP; ColoFlex for Colonoscopy; and AlveoFlex for Bronchoscopy and Alveoscopy. The company is also involved in the development of pre-clinical research systems, including ProFlex microprobes; Laser Scanning Unit, a high-resolution fibered confocal microscope; and ImageCell software that quantifies data in real time for various applications, such as deep brain imaging, Angiogenesis, peripheral nervous system, GI cancer research, stem cells, and pancreatic cancer imaging. It primarily serves the gastroenterologists and pulmonologists. The company was founded in 2000 and is based in Paris, France.

112 Employees
Last Reported Date: 04/30/14
Founded in 2000

mauna kea technologies (MKEA) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

mauna kea technologies (MKEA) Key Developments

Mauna Kea Technologies Announces Board Changes

Mauna Kea Technologies announced at the shareholder meeting held on June 11, 2014, Marie Meynadier and Jean-Luc Boulnois were elected to the board of directors replacing Creadev's nominees the board, Bertrand de Talhouët and Marie-Laure Pochon, who are leaving the board. Marie Meynadier is the CEO of EOS Imaging. Jean-Luc Boulnois is the executive chairman of the board at Microline Surgical. The company also announced that Gilles Brisson will be succeeded as chairman of the board by Christopher McFadden, an independent member of the board since 2008. Current independent board member Andre-Michel Ballester remains on the board and Philippe Maes will no longer act as a board observer.

Mauna Kea Technologies SAS Presents at Gilbert Dupont Healthcare Conference, May-13-2014

Mauna Kea Technologies SAS Presents at Gilbert Dupont Healthcare Conference, May-13-2014 . Venue: Paris, France.

Mauna Kea Technologies Presents at Goldman Sachs Small & Mid - Cap Symposium, May-07-2014

Mauna Kea Technologies Presents at Goldman Sachs Small & Mid - Cap Symposium, May-07-2014 . Venue: London, United Kingdom.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
MKEA:FP €8.90 EUR +0.02

MKEA Competitors

Market data is delayed at least 15 minutes.

Company Last Change
MELA Sciences Inc $2.45 USD -0.10
Optiscan Imaging Ltd A$0.04 AUD +0.007
Verisante Technology Inc C$0.16 CAD +0.01
View Industry Companies

Industry Analysis


Industry Average

Valuation MKEA Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 11.2x
Price/Book 4.0x
Price/Cash Flow NM Not Meaningful
TEV/Sales 8.3x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact MAUNA KEA TECHNOLOGIES, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at